RIPK3 and melanoma: This was a more general phenomenon for DR signalling, as Dabrafenib also inhibited TRAIL (Supplementary Figures 4A and B) and TNF-mediated necroptosis (Supplementary Figures 4C and D), in line with a recent report in primary and transformed keratinocytes.38 Taken together, the absence of RIPK3 or blockade of RIPK3 activity by the respective inhibitors or the BRAF inhibitor Dabrafenib, but not Vemurafenib, are able to block DL-mediated necroptotic and, to some extent, apoptotic cell death in melanoma.